CONMED Corporation (NASDAQ:CNMD) declared a quarterly dividend on Tuesday, August 29th, RTT News reports. Stockholders of record on Friday, September 15th will be given a dividend of 0.20 per share by the medical technology company on Thursday, October 5th. This represents a $0.80 annualized dividend and a dividend yield of 1.58%. The ex-dividend date is Thursday, September 14th.

CONMED Corporation (NASDAQ:CNMD) traded up 0.703% on Wednesday, hitting $50.875. The stock had a trading volume of 16,997 shares. The firm’s 50-day moving average is $49.56 and its 200-day moving average is $48.22. The company has a market cap of $1.42 billion, a P/E ratio of 91.011 and a beta of 0.68. CONMED Corporation has a 52-week low of $37.60 and a 52-week high of $52.82.

CONMED Corporation (NASDAQ:CNMD) last announced its quarterly earnings data on Wednesday, July 26th. The medical technology company reported $0.41 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.41. The business had revenue of $197.20 million for the quarter, compared to analysts’ expectations of $194.50 million. CONMED Corporation had a return on equity of 8.38% and a net margin of 2.02%. The company’s revenue for the quarter was up 2.0% compared to the same quarter last year. During the same period last year, the firm earned $0.47 earnings per share. Equities research analysts anticipate that CONMED Corporation will post $1.87 earnings per share for the current fiscal year.

Several brokerages have recently issued reports on CNMD. BidaskClub upgraded CONMED Corporation from a “strong sell” rating to a “sell” rating in a research note on Monday, August 14th. TheStreet upgraded CONMED Corporation from a “c+” rating to a “b-” rating in a research note on Thursday, August 3rd. Needham & Company LLC increased their price objective on CONMED Corporation from $54.00 to $57.00 and gave the company a “buy” rating in a research note on Thursday, July 27th. KeyCorp reiterated a “hold” rating on shares of CONMED Corporation in a research note on Friday, August 25th. Finally, Zacks Investment Research cut CONMED Corporation from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Two analysts have rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $49.33.

ILLEGAL ACTIVITY NOTICE: “CONMED Corporation (CNMD) to Issue Quarterly Dividend of $0.20 on October 5th” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/13/conmed-corporation-cnmd-to-issue-quarterly-dividend-of-0-20-on-october-5th.html.

In other CONMED Corporation news, Director Jo Ann Golden sold 3,000 shares of the firm’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $50.00, for a total value of $150,000.00. Following the sale, the director now directly owns 19,782 shares in the company, valued at $989,100. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.62% of the stock is owned by company insiders.

About CONMED Corporation

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

Dividend History for CONMED Corporation (NASDAQ:CNMD)

Receive News & Stock Ratings for CONMED Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED Corporation and related stocks with our FREE daily email newsletter.